Published in Neurology on June 25, 2002
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nature (2015) 4.03
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest (2012) 3.65
Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature (2013) 3.55
Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol (2012) 3.46
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat Rev Neurosci (2011) 3.23
Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol (2011) 2.94
Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci U S A (2003) 2.83
Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol (2009) 2.66
Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol (2012) 2.65
CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci (2010) 2.18
Seeded growth of beta-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. Proc Natl Acad Sci U S A (2009) 2.15
Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging (2009) 2.14
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis (2009) 2.12
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics (2008) 2.11
Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 2.09
Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 2.04
Functional network disruption in the degenerative dementias. Lancet Neurol (2011) 1.98
Molecular mechanism for age-related memory loss: the histone-binding protein RbAp48. Sci Transl Med (2013) 1.97
Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer's disease risk groups. Neuroimage (2009) 1.89
Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med (2014) 1.85
Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry (2009) 1.85
Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol (2008) 1.85
Vascular pathology in the aged human brain. Acta Neuropathol (2010) 1.78
The neuropathology of genetic Parkinson's disease. Mov Disord (2012) 1.73
Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol (2010) 1.71
Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol (2009) 1.67
Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol (2012) 1.65
Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage (2011) 1.64
Lifespan brain activity, β-amyloid, and Alzheimer's disease. Trends Cogn Sci (2011) 1.63
The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron (2014) 1.59
Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther (2009) 1.57
Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet (2014) 1.56
Multimodality Review of Amyloid-related Diseases of the Central Nervous System. Radiographics (2016) 1.53
Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci (2015) 1.53
Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol (2013) 1.52
Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. J Biol Chem (2009) 1.52
C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol (2013) 1.51
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51
Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease. Neurobiol Aging (2008) 1.49
Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathol (2012) 1.48
Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol (2009) 1.47
Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol (2010) 1.46
An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun (2016) 1.45
Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders. Neurology (2015) 1.44
Amyloid pathology and axonal injury after brain trauma. Neurology (2016) 1.43
Regional β-amyloid burden does not correlate with cognitive or language deficits in Alzheimer's disease presenting as aphasia. Eur J Neurol (2015) 1.43
Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo? Eur J Nucl Med Mol Imaging (2004) 1.42
Neuropathologic alterations in mild cognitive impairment: a review. J Alzheimers Dis (2010) 1.40
Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity. PLoS One (2016) 1.40
Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients. Proc Natl Acad Sci U S A (2014) 1.34
Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data. BMC Neurol (2012) 1.33
Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. Am J Pathol (2011) 1.32
Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain (2015) 1.31
Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies. Acta Neuropathol (2010) 1.31
PART is part of Alzheimer disease. Acta Neuropathol (2015) 1.31
Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. Acta Neuropathol (2015) 1.30
Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord (2008) 1.30
Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease. Biol Psychiatry (2010) 1.29
Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathol (2009) 1.27
Aβ Deposition in aging is associated with increases in brain activation during successful memory encoding. Cereb Cortex (2011) 1.26
Focal right inferotemporal atrophy in AD with disproportionate visual constructive impairment. Neurology (2003) 1.25
Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. Neurology (2010) 1.22
Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology (2015) 1.21
Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol (2011) 1.20
Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol Aging (2010) 1.19
Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol (2007) 1.19
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol (2015) 1.17
In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Ann Neurol (2013) 1.17
Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med (2008) 1.16
Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun (2014) 1.16
A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimers Dement (2013) 1.15
Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol (2009) 1.14
Callosal atrophy in mild cognitive impairment and Alzheimer's disease: different effects in different stages. Neuroimage (2009) 1.13
Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathol (2012) 1.13
Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther (2014) 1.11
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Sci Transl Med (2016) 1.11
Analysis of Alzheimer's disease severity across brain regions by topological analysis of gene co-expression networks. BMC Syst Biol (2010) 1.11
Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. Neurology (2013) 1.10
Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers. AIDS (2012) 1.09
Concomitant progressive supranuclear palsy and chronic traumatic encephalopathy in a boxer. Acta Neuropathol Commun (2014) 1.09
FMRI of working memory in patients with mild cognitive impairment and probable Alzheimer's disease. Eur Radiol (2005) 1.09
Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease. J Bioenerg Biomembr (2009) 1.09
Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region. Eur J Nucl Med Mol Imaging (2009) 1.08
Extracellular monomeric tau protein is sufficient to initiate the spread of tau protein pathology. J Biol Chem (2013) 1.07
How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II. J Neural Transm (Vienna) (2006) 1.07
Update on amyloid imaging: from healthy aging to Alzheimer's disease. Curr Neurol Neurosci Rep (2009) 1.07
Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. Brain (2014) 1.06
Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med (2012) 1.06
Mapping the effect of APOE epsilon4 on gray matter loss in Alzheimer's disease in vivo. Neuroimage (2009) 1.05
Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: implications for amyloid imaging. J Alzheimers Dis (2012) 1.04
Early detection of Alzheimer's disease using PiB and FDG PET. Neurobiol Dis (2014) 1.04
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res (2004) 7.06
Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol (2006) 6.20
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature (2010) 5.26
Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol (2006) 4.56
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Mutations in a human ROBO gene disrupt hindbrain axon pathway crossing and morphogenesis. Science (2004) 3.01
Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol (2009) 2.87
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol (2002) 2.46
Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol (2002) 2.37
Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord (2006) 2.31
100 years of Lewy pathology. Nat Rev Neurol (2012) 2.15
Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol (2003) 2.10
Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol (2009) 2.09
Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol (2010) 1.86
Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol (2008) 1.85
Spinocerebellar ataxia 2 (SCA2). Cerebellum (2008) 1.84
Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol (2003) 1.82
Neuroanatomical characteristics of the human pre-Bötzinger complex and its involvement in neurodegenerative brainstem diseases. Brain (2010) 1.75
A timeline for Parkinson's disease. Parkinsonism Relat Disord (2009) 1.75
Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One (2009) 1.71
Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol (2003) 1.64
Mapping local hippocampal changes in Alzheimer's disease and normal ageing with MRI at 3 Tesla. Brain (2008) 1.61
The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ (2006) 1.55
Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol (2002) 1.51
Brain pathology of spinocerebellar ataxias. Acta Neuropathol (2012) 1.39
Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci (2003) 1.37
SCA3: neurological features, pathogenesis and animal models. Cerebellum (2008) 1.31
PART is part of Alzheimer disease. Acta Neuropathol (2015) 1.31
The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann N Y Acad Sci (2004) 1.29
Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res Mol Brain Res (2002) 1.27
Parkinson's disease: the dual hit theory revisited. Ann N Y Acad Sci (2009) 1.27
Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson's disease. Neuroimage (2010) 1.26
Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases. J Alzheimers Dis (2006) 1.25
Neurodegeneration in normal brain aging and disease. Sci Aging Knowledge Environ (2004) 1.24
Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J Alzheimers Dis (2001) 1.20
Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci (2006) 1.19
Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med (2008) 1.16
Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol (2002) 1.14
The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies. Brain Pathol (2014) 1.11
Spinal cord lesions in sporadic Parkinson's disease. Acta Neuropathol (2012) 1.09
Argyrophilic grain disease in demented subjects presenting initially with amnestic mild cognitive impairment. J Neuropathol Exp Neurol (2006) 1.09
Lewy pathology and neurodegeneration in premotor Parkinson's disease. Mov Disord (2012) 1.06
Assessing fetal nerve cell grafts in Parkinson's disease. Nat Med (2008) 1.04
Biochemical analysis of tau proteins in argyrophilic grain disease, Alzheimer's disease, and Pick's disease : a comparative study. Am J Pathol (2002) 1.04
First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann Neurol (2010) 1.03
Staging of sporadic Parkinson disease-related alpha-synuclein pathology: inter- and intra-rater reliability. J Neuropathol Exp Neurol (2005) 1.03
Neurofibrillary changes of the Alzheimer type in very elderly individuals: neither inevitable nor benign: Commentary on "No disease in the brain of a 115-year-old woman". Neurobiol Aging (2008) 1.02
High prevalence of thorn-shaped astrocytes in the aged human medial temporal lobe. Neurobiol Aging (2004) 0.97
Molecular evolution and genetics of the Saitohin gene and tau haplotype in Alzheimer's disease and argyrophilic grain disease. J Neurochem (2004) 0.97
Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. J Neurol Neurosurg Psychiatry (2012) 0.96
TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol (2014) 0.96
Stages of granulovacuolar degeneration: their relation to Alzheimer's disease and chronic stress response. Acta Neuropathol (2011) 0.93
Inverse relationship between cerebrovascular lesions and severity of lewy body pathology in patients with lewy body diseases. J Neuropathol Exp Neurol (2010) 0.93
Axonal inclusions in spinocerebellar ataxia type 3. Acta Neuropathol (2010) 0.91
Neuroanatomy and pathology of sporadic Alzheimer's disease. Adv Anat Embryol Cell Biol (2015) 0.89
Up-regulation of cell division cycle (cdc) 2 kinase in neurons with early stage Alzheimer's disease neurofibrillary degeneration. Acta Neuropathol (2002) 0.89
A not entirely benign procedure: progression of Parkinson's disease. Acta Neuropathol (2008) 0.87
ATXN2-CAG42 sequesters PABPC1 into insolubility and induces FBXW8 in cerebellum of old ataxic knock-in mice. PLoS Genet (2012) 0.86
Apolipoprotein E co-localizes with newly formed amyloid beta-protein (Abeta) deposits lacking immunoreactivity against N-terminal epitopes of Abeta in a genotype-dependent manner. Acta Neuropathol (2005) 0.86
Characterization of human melatonin synthesis using autoptic pineal tissue. Endocrinology (2006) 0.86
Cognitive function in multiple system atrophy of the cerebellar type. Mov Disord (2006) 0.86
Dissociation of grey and white matter reduction in spinocerebellar ataxia type 3 and 6: a voxel-based morphometry study. Neurosci Lett (2006) 0.86
Association of the glutathione S-transferase omega-1 Ala140Asp polymorphism with cerebrovascular atherosclerosis and plaque-associated interleukin-1 alpha expression. Stroke (2007) 0.84
Relationship of apolipoprotein E and age at onset to Parkinson disease neuropathology. J Neuropathol Exp Neurol (2006) 0.84
Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer's disease. Neurodegener Dis (2005) 0.83
Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson's disease: an anatomical study. Acta Neuropathol (2009) 0.83
Amyloid-β may be released from non-junctional varicosities of axons generated from abnormal tau-containing brainstem nuclei in sporadic Alzheimer's disease: a hypothesis. Acta Neuropathol (2013) 0.82
Spinocerebellar ataxia type 2 (SCA2): identification of early brain degeneration in one monozygous twin in the initial disease stage. Cerebellum (2011) 0.81
Paraffin sections of 70-100 μm: a novel technique and its benefits for studying the nervous system. J Neurosci Methods (2013) 0.80
Intranuclear aggregation of nonexpanded ataxin-3 in marinesco bodies of the nonhuman primate substantia nigra. Exp Neurol (2002) 0.79
Age-dependent association between butyrylcholinesterase K-variant and Alzheimer disease-related neuropathology in human brains. Neurosci Lett (2002) 0.78
Functional neuroanatomy of the human premotor oculomotor brainstem nuclei: insights from postmortem and advanced in vivo imaging studies. Exp Brain Res (2008) 0.77
First patho-anatomical investigation of the brain of a SCA19 patient. Neuropathol Appl Neurobiol (2014) 0.77
Presence of severe neuroinflammation does not intensify neurofibrillary degeneration in human brain. Glia (2013) 0.76
Pallido-nigral spheroids in nonhuman primates: accumulation of heat shock proteins in astroglial processes. Acta Neuropathol (2001) 0.76
Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff. J Parkinsons Dis (2017) 0.75
Erratum to: Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol (2015) 0.75
Homozygosity for the K variant of BCHE gene increases the risk for development of neurofibrillary pathology but not amyloid deposits at young ages. Acta Neuropathol (2007) 0.75
Irradiation with X-rays phase-advances the molecular clockwork in liver, adrenal gland and pancreas. Chronobiol Int (2014) 0.75